Form 4: RA Capital Management Reports Acquisition of Stock Options in Aerovate Therapeutics

RA Capital Management and related entities report acquiring stock options in Aerovate Therapeutics, Inc.

Summary

• RA Capital Management, L.P., along with related entities and individuals, filed a Form 4 disclosing changes in beneficial ownership of Aerovate Therapeutics, Inc. securities.
• The report details the acquisition of stock options by Joshua Resnick, a Senior Managing Director of RA Capital Management, who serves on Aerovate Therapeutics' board of directors.
• These options, representing the right to buy 12,500 shares of common stock at an exercise price of $18.90, were granted on June 5, 2024, and will vest on the earlier of June 5, 2025, or the next annual meeting of the Issuer's stockholders.
• The options expire on June 4, 2034.
• RA Capital Management, RA Capital Healthcare Fund, RA Capital Nexus Fund, Peter Kolchinsky, and Rajeev Shah disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest therein.
• Mr. Resnick is obligated to turn over any net cash or stock received upon exercise of the option to RA Capital Management, which will offset advisory fees owed by the Fund to the Adviser.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports a transaction.

Positives

• The acquisition of stock options by a director could signal confidence in the future performance of Aerovate Therapeutics.

Future Outlook

The document does not contain specific forward-looking statements regarding Aerovate Therapeutics' future performance.

Management Comments

• RA Capital Management, RA Capital Healthcare Fund, RA Capital Nexus Fund, Peter Kolchinsky, and Rajeev Shah disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest therein.
• Joshua Resnick is obligated to turn over any net cash or stock received upon exercise of the option to RA Capital Management, which will offset advisory fees owed by the Fund to the Adviser.

Industry Context

This filing is typical for investment firms holding significant positions in publicly traded companies, especially when changes in ownership occur or new equity-based compensation is granted to insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders, aligning with SEC regulations.
• The vesting schedule and exercise price of the stock options are typical for executive compensation packages in the biotechnology industry.
• Similar filings can be observed for other healthcare-focused investment firms like Orbimed, Deerfield, and Baker Bros. when their directors or affiliated entities engage in transactions involving company stock.

Stakeholder Impact

• The acquisition of stock options could have a slightly positive impact on shareholder sentiment, as it indicates confidence from a major investor.

Key Dates